MCM
ALNY icon

Moore Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Moore Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-80,000
Closed -$14.2M – 432
2023
Q3 		$14.2M Buy
+80,000
New +$15.3M 0.26% 71

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Moore Capital Management's ALNY Position: Q4 2025 in Review

Moore Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,104 shares — an estimated $1.87M sold.

Moore Capital Management first reported a position in ALNY in Q1 2015 and held it in 6 quarters. The position peaked at $4.25M in Q3 2022. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Moore Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Moore Capital Management sold 4,104 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $1.87M.
  • Moore Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Moore Capital Management's Alnylam Pharmaceuticals position peaked at $4.25M in Q3 2022.
  • 849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Moore Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.